J&J's paliperidone LA shows 13-week control
Johnson & Johnson's investigational long-acting schizophrenia drug paliperidone palmitate demonstrated statistically-significant symptom control compared with placebo, according to the results of a 13-week study.
The US health care major says that statistical significance was seen at all doses of the antipsychotic tested (25mg, 100mg, and 150mg equivalent), when given every four weeks with a 150mg initiation dose.
The agent is a long-acting formulation of the oral drug Invega (paliperidone extended-release), which is approved for the acute and maintenance treatment of schizophrenia. Because of the delivery systems used, LA formulations may produce more consistent levels of the drug, J&J noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze